## WAT: Waters Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -0.9% below STRENGTH zone (3.0-6.0%); PEG 6.41 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($365.27)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. Waters-Becton-Dickinson deal receives antitrust clearance in the US**
- Source: MLex | 20251212T130600 | Bullish | Relevance: 100%
- Waters Corp.'s acquisition of Becton, Dickinson and Co.'s Biosciences & Diagnostic Solutions division for $17.5 billion has successfully gained antitrust clearance in the United States. This significant merger can now proceed after receiving the necessary regulatory approval. The article, however, does not provide further details on the implications or conditions of this clearance.

**2. Waters Corp. stock rating upgraded to Outperform by Wolfe Research**
- Source: Investing.com UK | 20251210T120902 | Bullish | Relevance: 100%
- Wolfe Research upgraded Waters Corp. (NYSE:WAT) to Outperform with a $480.00 price target, citing above-average core growth potential, an attractive free cash flow profile, and strong management. Despite potential near-term premium degradation from the BD Life Sciences integration, Wolfe Research believes Waters shares are undervalued due to the company's attractive end market and strong financial prospects. This upgrade follows strong Q3 2025 results that surpassed analyst expectations, leading to adjusted price targets from other investment firms.

**3. Waters Corporation $WAT Holdings Cut by London Co. of Virginia**
- Source: MarketBeat | 20251214T132331 | Neutral | Relevance: 100%
- London Co. of Virginia reduced its stake in Waters Corporation (NYSE:WAT) by 2.8% in Q2, now holding 580,436 shares valued at approximately $202.6 million. Institutional investors currently own about 94.01% of the medical instruments supplier, which has a "Moderate Buy" consensus rating and a target price of $390.31. Waters reported quarterly EPS of $2.29 on revenues of $608.55 million and has a market capitalization of $22.94 billion.

**4. Thrivent Financial for Lutherans Sells 75,008 Shares of Waters Corporation $WAT**
- Source: MarketBeat | 20251214T132331 | Somewhat-Bullish | Relevance: 100%
- Thrivent Financial for Lutherans has reduced its stake in Waters Corporation (NYSE:WAT) by selling 75,008 shares, decreasing its position by 21.3% to 277,051 shares. This move values their remaining holding at approximately $96.7 million. Waters Corporation, a medical instruments supplier, saw several other institutional investors also adjust their holdings, while Wall Street analysts have provided mixed ratings with a consensus target price of $390.31.

**5. Waters Corp Hits 80-Plus Relative Strength Rating Benchmark**
- Source: Investor's Business Daily | 20251211T080839 | Bullish | Relevance: 100%
- Waters Corp (WAT) has achieved an 80-plus Relative Strength (RS) Rating, climbing from 77 to 81. This upgrade indicates improving technical performance and market leadership for the stock. Investors are advised to focus on stocks with an RS Rating of 80 or higher for their watch lists.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-10 | Wolfe Research | $480 | $0 | 0% |
| 2025-12-02 | Morgan Stanley | $423 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-10 | Wolfe Research | up | Outperform |
| 2025-12-02 | Morgan Stanley | init | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 2 ($0.00M) |
| Sells | 1 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 52.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 2 |

**Top Holders:**
- Vanguard Group Inc: 12.9% (+3.3%)
- Blackrock Inc.: 10.2% (-7.6%)
- Fundsmith LLP: 6.6% (+9.6%)
- Massachusetts Financ: 4.5% (+44.3%)
- State Street Corpora: 4.5% (+0.1%)

### Key Risks

1. Valuation stretched: PEG 6.4x requires aggressive growth execution.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 6.41 signals overvaluation risk, limited margin of safety. Forward P/E 26.9x stretched relative to 9% growth. Quality metrics strong (ROE 33%, ROA 12%, margin 21%). Institutional flow bullish (8 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $22.9B |
| Beta | 1.16 |
| 52W Range | $275.05 - $423.56 |
| Short Interest | 5.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 6.41 |
| Forward P/E | 26.9 |
| Current P/E | 29.4 |
| YoY Growth | 9.0% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -2.8% to -0.9% (+1.8% in 5 days), confirming momentum buildup. Below STRENGTH zone by 3.9pp (needs >3.0% for momentum thesis). MRS_5 turning positive (0.0%) - potential reversal signal. Long-term uptrend intact (above SMA200 at 1.14x) but short-term weakness (below SMA20). MACD histogram bearish (-3.18), momentum weakening. RSI neutral at 51. OFD pattern: -MTN (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -0.94% (CS: 18) | Neutral |
| RSI_14 | 51.0 | Neutral |
| MACD Histogram | -3.18 | Bearish |
| vs SMA20 | 0.983x | Below |
| vs SMA50 | 1.051x | Above |
| vs SMA200 | 1.136x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $385.33
- **Stop Loss:** $365.27 (5.2% risk)
- **Target:** $405.39 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 49
- **Position Value:** $18,881.17
- **Portfolio %:** 18.88%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX remains calm at 15.74 while breadth shows modest participation at 54%, suggesting selective positioning. FOMC meeting in 4 days creates near-term uncertainty but no systemic stress evident.*

### Earnings

**Next:** 2026-02-11 (Est: $4.51)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.22 | $3.40 | +5.5% |
| 2025Q2 | $2.94 | $2.95 | +0.3% |
| 2025Q1 | $2.22 | $2.25 | +1.2% |
| 2024Q4 | $4.03 | $4.10 | +1.7% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*